The ongoing conflict involving the United States, Israel, and Iran has significant repercussions for global pharmaceutical supply chains. This situation, which escalated on February 28, 2026, has disrupted critical logistics pathways, particularly affecting regions like Dubai, a vital hub for pharmaceutical logistics and air cargo transshipments. Experts warn that the impact of this conflict could reverberate across multiple markets, influencing everything from drug availability to pricing.
Disruption of Key Logistics Hubs
Dubai serves as an essential conduit for pharmaceutical exports, especially from major Indian hubs like Bengaluru. The United Arab Emirates (UAE) has experienced infrastructure damage due to retaliatory strikes from Iran, leading to the closure of airspace and the suspension of operations at Dubai International Airport (DXB) and the Al Maktoum International Airport (DWC). These disruptions have significant implications for air cargo operations, which are crucial for transporting high-value, time-sensitive pharmaceuticals such as active pharmaceutical ingredients (APIs) and vaccines.
Air Cargo Paralysis
According to industry specialist Vikas Nim, the current conflict has caused a state of paralysis in air freight, a primary channel for pharmaceutical logistics. The reliance on air cargo for temperature-sensitive shipments poses a unique challenge, as delays can lead to spoilage and regulatory complications. With DXB fully suspended, major carriers like Emirates SkyCargo have halted operations, leading to immediate backlogs in pharmaceutical shipments. The necessity for rerouting through alternative hubs—such as Istanbul or Frankfurt—results in increased transit times and costs, straining already sensitive supply chains.
Impact on Sea Freight
The fallout from the conflict has also affected sea freight, particularly through Jebel Ali Port, a crucial gateway for bulk and containerized pharmaceutical shipments. Major shipping lines, including MSC and Maersk, have ceased bookings in the Middle East and are avoiding the Strait of Hormuz due to heightened security concerns. This decision complicates the logistics for bulk APIs and generics, further exacerbating the already strained supply chains. Any rerouting that necessitates a longer journey, such as via the Cape of Good Hope, not only prolongs delivery times by 10 to 15 days but also increases freight costs and risks temperature excursions in cold-chain logistics.
Risks to Product Integrity
As delays accumulate, significant risks to cold-chain logistics emerge. Temperature-sensitive products, including vaccines and monoclonal antibodies, face a higher likelihood of spoilage due to extended transit times. Pharmaceutical companies may encounter regulatory hurdles, as temperature deviations could necessitate costly emergency airlifts or local stock adjustments. The overall impact on product integrity is a pressing concern for the industry.
Escalating Costs and Insurance Premiums
The financial implications of the conflict extend beyond logistical delays. War-risk insurance premiums have surged, and fuel surcharges are climbing, leading to a potential 30-50% increase in overall logistics costs for affected routes in the short term. The economic impact is compounded by the urgency of pharmaceutical exports, as companies grapple with both rising costs and the imperative to maintain supply continuity.
The Indian Pharmaceutical Sector
Focusing on India, experts have raised alarms about potential disruptions for Indian pharmaceutical exporters, many of whom have a robust presence in the Middle East. As Dubai remains a critical transit point for exports to the Gulf Cooperation Council (GCC) and African markets, prolonged delays could result in inventory shortages and production slowdowns. The ripple effects of these supply chain disruptions could significantly impact broader Indian exports as well.
Contingency Plans and Future Strategies
With no immediate resolution to the conflict on the horizon, pharmaceutical companies are activating contingency plans. These include identifying alternative routing options, increasing local warehousing capabilities, and exploring air-sea hybrid solutions. Many firms are also considering nearshoring and dual-sourcing strategies to mitigate risks associated with geopolitical instability. For Indian pharmaceutical companies, staying informed through channels like Emirates SkyCargo and the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is essential.
The ongoing geopolitical strife underscores the fragility of global supply chains, particularly within the pharmaceutical sector. The challenges currently faced will likely necessitate a reevaluation of logistics strategies and risk management frameworks across the industry.
Takeaways
- The UAE’s closure of airspace and port operations has severely disrupted pharmaceutical logistics.
- Air freight paralysis is creating significant backlogs and increasing costs for time-sensitive shipments.
-
Supply chain disruptions raise concerns about product integrity and regulatory compliance.
-
Indian pharmaceutical exporters are particularly vulnerable due to their reliance on UAE as a transit hub.
-
Contingency planning and alternative routing are critical for navigating ongoing geopolitical risks.
In conclusion, the current conflict has highlighted vulnerabilities in pharmaceutical supply chains, urging companies to adapt and innovate in their logistics strategies. The need for resilience in the face of geopolitical uncertainty has never been more apparent, prompting a critical reassessment of supply chain dependencies and risk management practices.
Read more → www.pharmabiz.com